Monopar Therapeutics Inc MNPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
-
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
-
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
-
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Trading Information
- Previous Close Price
- $71.80
- Day Range
- $68.81–71.01
- 52-Week Range
- $50.07–124.82
- Bid/Ask
- $47.66 / $69.50
- Shares Outstanding
- 6.71M
- Market Cap
- $464.95M
- Volume/Avg
- 161,602 / 205,604
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 22
- Website
- https://www.monopartx.com
Valuation
|
Metric
|
MNPR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.55 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MNPR
|
|---|---|
Quick Ratio | 33.44 |
Current Ratio | 33.56 |
Interest Coverage | — |
Quick Ratio
MNPR
Profitability
|
Metric
|
MNPR
|
|---|---|
Return on Assets (Normalized) | −10.23% |
Return on Equity (Normalized) | −10.47% |
Return on Invested Capital (Normalized) | −14.01% |
Return on Assets
MNPR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|V%?gwT | LOCK|rhnfZ | $127B | |||
| Moderna Inc
MRNA
| LOCK|Cs$Q@?% | LOCK|<& | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%!<%Hl! | LOCK|Ljd@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|pV<W@z | LOCK|vJ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|x!NZ@H | LOCK|NJ! | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gD^F!v | LOCK|^V&T^ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#Q$RF?& | LOCK|X%M! | $27B | |||
| Incyte Corp
INCY
| LOCK|>m%$Sz! | LOCK|@>L | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|SFZT!&@ | LOCK|zc | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<G#tT@B | LOCK|&<C | $14B |
United States